Dr. Shahbazi’s lab is focused on developing CRISPR nanotherapeutics as a one-time therapy, and making these therapeutics available to all patients in the world.
Currently, along with developing disease specific CRISPR nanotherapeutics, Shahbazi lab is working on developing novel CRISPR nanoformulations to generate engineered T cells with cancer specific T cell receptors (TCR), or chimeric antigen receptor-modified T (CAR-T) cells for cancer immunotherapy.
